© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90381 refers to a specific monoclonal antibody vaccine designed to provide protection against respiratory syncytial virus (RSV). This vaccine is administered in a 1 mL dosage via intramuscular injection. The primary function of this vaccine is to stimulate the recipient's immune system, enabling it to produce antibodies that can effectively combat RSV upon exposure. RSV is a highly contagious virus that is known to cause acute respiratory infections, particularly affecting infants, young children, and vulnerable populations such as the elderly or those with compromised immune systems. The virus typically circulates during the fall and winter months, making seasonal vaccination crucial for at-risk groups. The monoclonal antibody contained in this vaccine is engineered to mimic the natural immune response, providing a proactive defense against RSV. This is especially important for infants and neonates during their first RSV season, as they are at a heightened risk for severe illness, including pneumonia and potential hospitalization. The administration of this vaccine is a preventive measure aimed at reducing the incidence of RSV-related complications in young children and infants who are particularly susceptible to the virus.
© Copyright 2025 Coding Ahead. All rights reserved.
The monoclonal antibody vaccine represented by CPT® Code 90381 is indicated for specific populations at high risk for severe respiratory syncytial virus (RSV) infection. The following conditions and circumstances warrant the administration of this vaccine:
The administration of the monoclonal antibody vaccine involves several key procedural steps to ensure safety and efficacy:
Following the administration of the monoclonal antibody vaccine, patients are generally advised to observe for any side effects, which may include mild reactions such as soreness at the injection site, low-grade fever, or irritability. It is important for caregivers to monitor the child for any unusual symptoms and to report these to a healthcare provider if they occur. The vaccine is intended to provide protection throughout the RSV season, and it is recommended that the administration occurs before the onset of the RSV season to maximize its effectiveness. Additionally, healthcare providers may offer guidance on ongoing preventive measures and monitoring for RSV symptoms during the season.
Short Descr | RSV MONOC ANTB SEASN 1 ML IM | Medium Descr | RSV MONOCLONAL ANTB SEASONAL DOSE 1 ML IM USE | Long Descr | Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use | Status Code | Non-Covered Service | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Items and Services Not Billable to the MAC | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit |
Date
|
Action
|
Notes
|
---|---|---|
2024-01-01 | Added | First appearance in CodeBook |
2023-07-17 | Added | Code released on June 30, 2023, FDA approval received and effective July 17, 2023. |